Reimbursement Review Reports


( Last Updated : April 2, 2015)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Adcetris Brentuximab Vedotin Primary cutaneous anaplastic large cell Lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) Reimburse with clinical criteria and/or conditions Complete
Adcetris Brentuximab vedotin Systemic Anaplastic Large Cell Lymphoma Reimburse with clinical criteria and/or conditions Complete
Adcetris (Resubmission) Brentuximab Vedotin Hodgkin lymphoma (HL) Do not reimburse Complete
Adcirca Tadalafil Pulmonary arterial hypertension List with clinical criteria and/or conditions Complete
Adderall XR Mixed amphetamine salts Attention deficit hyperactivity disorder Do not list Complete
Adderall XR Mixed amphetamine salts Attention deficit hyperactivity disorder, Adult Do not list Complete
Adderall XR Mixed amphetamine salts Attention deficit hyperactivity disorder Withdrawn
Adempas Riociguat Pulmonary arterial hypertension (WHO group 1) List with clinical criteria and/or conditions Complete
Adempas Riociguat Chronic thromboembolic pulmonary hypertension List with criteria/condition Complete
Adlyxine lixisenatide Diabetes mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete